Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective

Clinical Therapeutics (2017) - Comments
pubmed: 28189363 doi: 10.1016/j.clinthera.2017.01.017 issn: 0149-2918 issn: 1879-114x

Stefano Capri, Camillo Porta, Thomas E. Delea